WS #12752
Holding: newest synthesis is 50d old
Eli Lilly offers $6.75/share (up to $9.25 with CVRs) for Atai Beckley, a 72.6% premium, boosting psychedelics biotech sector.
Eli Lilly Acquires Atai Beckley for Psychedelics
Eli Lilly offers $6.75/share (up to $9.25 with CVRs) for Atai Beckley, a 72.6% premium, boosting psychedelics biotech sector.